Team Leader
Scientist
TEAM LEADER : Eric Tartour & Magali Terme
Mail : eric.tartour@inserm.fr / magali.terme@inserm.fr
Phone : +33 1 53 98 80 26
Localisation : Lab 177, 1st Floor
DOCTORAL SCHOOL : ED 562 – BIO SCIENCE PARIS CITE – Université PARIS CITE
The main objective of the team is to better understand the link between tumor angiogenesis and immunity. It is structured in 2 groups, one directed by Magali Terme on “angiogenesis and immunity” and the other by Eric Tartour on “optimization of cancer immunotherapy strategies”; this last axis is very focused on anti-tumor vaccination. There are strong relationships between the two areas, notably through the analysis of the mechanism of action of anti-angiogenic agents and the interest of their use to improve cancer immunotherapy. In the same way, the discoveries of the “angiogenesis and immunity” axis, such as the demonstration of the role of VEGF in increasing the expression of inhibitory receptors on T lymphocytes (Voron/Terme JEM 2015) or the action of HIF in promoting both angiogenesis via the induction of VEGF and immunosuppression via the increase in CD70 (Benhamouda N et al CCR 2022), have direct applications to the development of biomarkers or new therapeutic targets/strategies linked to angiogenesis for cancer immunotherapy.
1. Impact of pro-angiogenic molecules on the immune cells
Regarding immunotherapy, A Carpentier’s group has demonstrated the adjuvant properties of melanin (Cuzzubbo S Int J Mol Sci 2022). E Tartour’s group showed that the B subunit of shiga toxin was an original and competitive synthetic vector for inducing memory resident T cells and mucosal immunity (Karaki S et al JITC 2021)(Billet A et al Biomaterials In Press).
We have also shown that targeting other pro-angiogenic molecules such as HGF could also have an immunomodulatory role by reducing the concentrations of regulatory T lymphocytes (Palle J et al Cancers 2022).
2. Link between angiogenesis and cancer
Various groups of the team have also some important work linking myeloid cells, angiogenesis and cancer. Tie2 positive myeloid cells known for their proangiogenic properties has emerged as a potentially interesting biomarker for predicting response to anti-angiogenic therapy (Oudard S et al Cells 2021). M Terme reported that HGF target monocytes which favors the expansion of regulatory T cells (Palle J et al Cancers 2021). Thi Tran also showed that a high-fat diet accelerated tumour growth via a population of myeloid cells that produced VEGF (Tran T et al Nat Commun 2022).
Finally, C Tanchot has reported the syngergistic effect of cancer vaccine and anti-angiogenic molecules via the reprogramming of the immunosuppressive microenvironment (Mougel A et al Oncoimmunol 2022).
Team Leader
Scientist
Scientist
Clinician
Clinician
Clinician
Clinician
Clinician
Clinician
Clinician
Clinician
Clinician
PhD Students
PhD Student
PhD Students
PhD Students
Engineer
Engineer
Engineer
Engineer
Engineer
Engineer
Enginners and Technicians
Engineers and Technicians
Mevyn Nizard, 1rst Prize “Congrès Jeunes Chercheurs Prix René Descartes – 2014 “
Mevyn Nizard, best oral communication “8th Meeting of the Vaccinology Club – 2013 – Institut Pasteur, Paris”
Labellisation Fondation ARC (2025-2028)
Immunokare (financement privé)
DIM ITAC Region Ile de France (2024-2027)
COALA (INCA : 2024-2028)
Fondation Bristol-Myers Squibb pour la Recherche en Immuno-Oncologie (2024-2026)
Ligue contre le cancer (2024-2026)
Plan d’Investissement France 2030 – ANR-18-IDEX-0001 (Université Paris Cité) (2024-2026)
ANR RPIB : Selectimmunoonco (2015-2018)
INCA : Predimel (2015-2018)
INCA PLBio : 2017-2019
SIRIC CARPEM
Labex Immuno-Oncology
Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies. Damei I, Caidi A, Auclin E, Adam J, Mella S, Hasan M, Tartour E, Robert C, Corgnac S, Mami-Chouaib F. Nat Commun. 2025 Jul 1;16(1):5588. doi: 10.1038/s41467-025-60657-w.
The CD70-CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target. Sam I, Ben Hamouda N, Alkatrib M, Gonnin C, Siska PJ, Oudard S, Lebbé C, Tartour E. Clin Cancer Res. 2025 Jul 15;31(14):2872-2881. doi: 10.1158/1078-0432.CCR-24-2668.
Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma. Sam I, Benhamouda N, Biard L, Da Meda L, Desseaux K, Baroudjan B, Nakouri I, Renaud M, Sadoux A, Alkatrib M, Deleuze JF, Battistella M, Shen Y, Resche-Rigon M, Mourah S, Lebbe C, Tartour E. EMBO Mol Med. 2025 May;17(5):909-922. doi: 10.1038/s44321-025-00203-9. Epub 2025 Mar 27.
Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy. Joshkon A, Traboulsi W, Terme M, Bachelier R, Fayyad-Kazan H, Dignat-George F, Foucault-Bertaud A, Leroyer AS, Bardin N, Blot-Chabaud M. Mol Cancer Ther. 2025 Feb 4;24(2):275-285. doi: 10.1158/1535-7163.MCT-24-0008.
Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma. Pourmir I, Benhamouda N, Tran T, Roux H, Pineau J, Gey A, Munoz A, Mabrouk N, Epaillard N, Verkarre V, Vano YA, Tartour E, Oudard S. J Exp Clin Cancer Res. 2025 Feb 14;44(1):54. doi: 10.1186/s13046-025-03293-y.
CD57+ EMRA CD8+ T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy. Gonnin C, Leemans M, Canoui-Poitrine F, Lebraud M, Corneau A, Roquebert L, Caillet P, Gay P, Canovas J, Histe A, Blanc C, El-Sissy C, Larbi A, Poisson J, Ober P, Boudou-Rouquette P, Natella PA, Vallet H, Saadaoui B, Layese R, Tartour E, Paillaud E, Granier C. Immun Ageing. 2024 Dec 27;21(1):89. doi: 10.1186/s12979-024-00487-4.
Differential predictive value of resident memory CD8+T cell subpopulations in patients with non-small-cell lung cancer treated by immunotherapy. Paolini L, Tran T, Corgnac S, Villemin JP, Wislez M, Arrondeau J, Johannes L, Ulmer J, Vieillard LV, Pineau J, Gey A, Quiniou V, Barennes P, Pham HP, Gruel N, Hasan M, Libri V, Mella S, De Percin S, Boudou-Rouquette P, Caidi A, Cremer I, Blons H, Leroy K, Laurent-Puig P, De Saint Basile H, Gibault L, Ravel P, Mami-Chouaib F, Goldwasser F, Fabre E, Damotte D, Tartour E. J Immunother Cancer. 2024 Dec 3;12(12):e009440. doi: 10.1136/jitc-2024-009440.
Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARS-CoV-2 mRNA vaccination. Benhamouda N, Besbes A, Bauer R, Mabrouk N, Gadouas G, Desaint C, Chevrier L, Lefebvre M, Radenne A, Roelens M, Parfait B, Weiskopf D, Sette A, Gruel N, Courbebaisse M, Appay V, Paul S, Gorochov G, Ropers J, Lebbah S, Lelievre JD, Johannes L, Ulmer J, Lebeaux D, Friedlander G, De Lamballerie X, Ravel P, Kieny MP, Batteux F, Durier C, Launay O, Tartour E. iScience. 2024 Jul 2;27(8):110441. doi: 10.1016/j.isci.2024.110441. eCollection 2024 Aug 16.
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, Lounici Y, Treilleux I, Just PA, Bataillon G, Savoye AM, Mouret-Reynier MA, Coquan E, Derbel O, Jeay L, Bouizaguen S, Labidi-Galy I, Tabone-Eglinger S, Ferrari A, Thomas E, Ménétrier-Caux C, Tartour E, Galy-Fauroux I, Stern MH, Terme M, Caux C, Dubois B, Ray-Coquard I. Nat Commun. 2024 Jul 16;15(1):5932. doi: 10.1038/s41467-024-47000-5.
Increased levels of GM-CSF and CXCL10 and low CD8+ memory stem T Cell count are markers of immunosenescence and severe COVID-19 in older people. Poisson J, El-Sissy C, Serret-Larmande A, Smith N, Lebraud M, Augy JL, Conti C, Gonnin C, Planquette B, Arlet JB, Hermann B, Charbit B, Pastre J, Devaux F, Ladavière C, Lim L, Ober P, Cannovas J, Biard L, Gulczynski MC, Blumenthal N, Péré H, Knosp C, Gey A, Benhamouda N, Murris J, Veyer D, Tartour E, Diehl JL, Duffy D, Paillaud E, Granier C. Immun Ageing. 2024 May 7;21(1):28. doi: 10.1186/s12979-024-00430-7.
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA). Legoux JL, Faroux R, Barrière N, Le Malicot K, Tougeron D, Lorgis V, Guerin-Meyer V, Bourgeois V, Malka D, Aparicio T, Baconnier M, Lebrun-Ly V, Egreteau J, Khemissa Akouz F, Terme M, Lepage C, Boige V. Cancers (Basel). 2024 Apr 16;16(8):1515. doi: 10.3390/cancers16081515.
A synthetic delivery vector for mucosal vaccination. Billet A, Hadjerci J, Tran T, Kessler P, Ulmer J, Mourier G, Ghazarian M, Gonzalez A, Thai R, Urquia P, Van Baelen AC, Meola A, Fernandez I, Deville-Foillard S, MacDonald E, Paolini L, Schmidt F, Rey FA, Kay MS, Tartour E, Servent D, Johannes L. Biomaterials. 2023 Nov;302:122298. doi: 10.1016/j.biomaterials.2023.122298. Epub 2023 Sep 5.
A synthetic delivery vector for mucosal vaccination. Billet A*, Hadjerci J*, Tran T*, Kessler P, Ulmer J, Mourier G, Ghazarian M, Gonzalez A, Thai R, Urquia P , Van Baelen AC, Meola A, Fernandez I, Deville-Foillard, MacDonald E, Paolini L, Schmidt F, Rey FA, Kau MS, Tartour E ╪, Servent D╪, Johannes L ╪. Biomaterials. In press * Contributed equally. ╪ co-corresponding author.
Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6Chi monocytes and differentiation to pro-angiogenic myeloid cells. Tran T, Lavillegrand JR, Lereverend C, Esposito B, Cartier L, Montabord M, Tran-Rajau J, Diedisheim M, Gruel N, Ouguerram K, Paolini L, Lenoir O, Pinteaux E, Brabencova E, Tanchot C, Urquia P, Lehmann-Che J, Le Naour R, Merrouche Y, Stockmann C, Mallat Z, Tedgui A, Ait-Oufella H, Tartour E, Potteaux S. Nat Commun. 2022 14.09 13(1):5399. doi: 10.1038/s41467-022-33034-0.(PMID: 36104342).
Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting. Mauge L, Phan L, Benhamouda N, Galy-Fauroux I, Badoual C, Topart D, Thiery-Vuillemin A, Le Moulec S, Guillot A, Cessot A, Mejean A, Albiges L, Tartour E, Fournier L, Helley D, Oudard S. Clin Oncol (R Coll Radiol). 2023 Mar;35(3):e245-e255. doi: 10.1016/j.clon.2022.11.012
CXCR6 expressing T cells: Functions and role in the control of tumors. Mabrouk N, Tran T, Sam I, Pourmir I, Gruel N, Granier C, Pineau J, Gey A, Kobold S, Fabre E, Tartour E. Front Immunol. 2022 Oct 12;13:1022136. doi: 10.3389/fimmu.2022.1022136. eCollection 2022.
Plasma CD27, a surrogate of the intratumoral CD27-CD70 interaction correlates with immunotherapy resistance in renal cell carcinoma. Benhamouda N, Sam I, Epaillard N, Gey A, Phan L, Pham HP, Gruel N, Saldmann A, Pineau J, Hasan M, Quiniou V, Nevoret C, Verkarre V, Libri V, Mella S, Granier C, Broudin C, Ravel P, De Guillebon E, Mauge L, Helley D, Jabla B, Chaput N, Albiges L, Katsahian S, Adam J, Mejean A, Adotevi O, Vano YA, Oudard S, Tartour E. Clin Cancer Res. 2022 Nov 14;28(22):4983-4994 (PMID: 36067339).
Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. Mougel A, Mejean F, Tran T, Adimi Y, Galy-Fauroux I, Kabore C, Mercier E, Urquia P, Terme M, Tartour E, Tanchot C. Oncoimmunology 2022 Aug 9;11(1):2110218. doi: 10.1080/2162402X.2022.2110218. eCollection (PMID: 35968405).
Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy. Cuzzubbo S, Roch B, Darrasse-Jèze G, Hosten B, Leclercq M, Vignal N, Banissi C, Tartour E, Carpentier AF. Int J Mol Sci. 2022 Nov 29;23(23):14975. doi: 10.3390/ijms232314975 (PMID: 36499300).
CXCR6 deficiency impairs cancer vaccine efficacy and CD8+resident memory T-cell recruitment in head and neck and lung tumors. Karaki S, Blanc C, Tran T, Galy-Fauroux I, Mougel A, Dransart E, Anson M, Tanchot C, Paolini L, Gruel N, Gibault L, Lepimpec-Barhes F, Fabre E, Benhamouda N, Badoual C, Damotte D, Donnadieu E, Kobold S, Mami-Chouaib F, Golub R, Johannes L, Tartour E. J Immunother Cancer. 2021 Mar;9(3):e001948. doi: 10.1136/jitc-2020-001948 (PMID: 33692218).
Targeting HGF/c-Met axis decreases circulating regulatory T cells accumulation in gastric cancer patients. Palle J, Hirsch L, Lapeyre-Prost A, Malka D, Bourhis M, Pernot S, Marcheteau E, Voron T, Castan F, Lacotte A, Benhamouda N, Tanchot C, François E, Ghiringhelli F, de la Fouchardière C, Zaanan A, Tartour E, Taieb J, Terme M. Cancers (Basel). 2021 Nov 5;13(21):5562. doi: 10.3390/cancers13215562 (PMID: 34771724).
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. Stephane Oudard , Nadine Benhamouda , Bernard Escudier , Patrice Ravel , Thi Tran , Emeline Levionnois , Sylvie Negrier , Philippe Barthelemy , Jean François Berdah , Marine Gross-Goupil , Cora N Sternberg , Petri Bono , Camillo Porta , Ugo De Giorgi , Omi Parikh , Robert Hawkins , Martin Highley , Jochen Wilke , Thomas Decker , Corinne Tanchot , Alain Gey , Magali Terme , Eric Tartour Cells 2021 Dec 22;11(1):17. doi: 10.3390/cells11010017.(PMID: 35011579).
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Bourhis M , Palle J, Galy-Fauroux I , Terme M, Front in Immunol 2021 March 29 12 : DOI : PMID: 33854498 10.3389/fimmu.2021.616837 (PMID 33854498).
Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. Mougel A, Terme M, Tanchot C Front in Immunol 2019 Mar 14 10 DOI : 10.3389/fimmu.2019.00467 (PMID 30923527).
